Log in

SpringWorks Therapeutics Stock Forecast, Price & News

+1.99 (+4.46 %)
(As of 09/29/2020 12:00 AM ET)
Today's Range
Now: $46.58
50-Day Range
MA: $44.00
52-Week Range
Now: $46.58
Volume222,686 shs
Average Volume179,454 shs
Market Capitalization$2.00 billion
P/E RatioN/A
Dividend YieldN/A
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; and Nirogacestat + belantamab mafodotin, which is in Phase 1b clinical trials for the treatment of relapsed or refractory multiple myeloma. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trials in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions, which is in preclinical studies in a range of tumor models with BRAF mutations or fusions. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline plc to develop combination approaches with nirogacestat and mirdametinib, as well as other standalone medicines. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SWTX



Sales & Book Value

Annual SalesN/A
Book Value$7.49 per share


Net Income$-58,310,000.00


Market Cap$2.00 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
+1.99 (+4.46 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SWTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SpringWorks Therapeutics (NASDAQ:SWTX) Frequently Asked Questions

How has SpringWorks Therapeutics' stock been impacted by Coronavirus?

SpringWorks Therapeutics' stock was trading at $33.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SWTX shares have increased by 40.2% and is now trading at $46.58.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of SpringWorks Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SpringWorks Therapeutics

When is SpringWorks Therapeutics' next earnings date?

SpringWorks Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for SpringWorks Therapeutics

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics (NASDAQ:SWTX) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.11.
View SpringWorks Therapeutics' earnings history

What price target have analysts set for SWTX?

6 analysts have issued twelve-month price targets for SpringWorks Therapeutics' stock. Their forecasts range from $32.00 to $58.00. On average, they anticipate SpringWorks Therapeutics' stock price to reach $46.40 in the next twelve months. This suggests that the stock has a possible downside of 0.4%.
View analysts' price targets for SpringWorks Therapeutics

Who are some of SpringWorks Therapeutics' key competitors?

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Bristol-Myers Squibb (BMY), BioXcel Therapeutics (BTAI), Gilead Sciences (GILD), TapImmune (MRKR), Opko Health (OPK) and Provention Bio (PRVB).

Who are SpringWorks Therapeutics' key executives?

SpringWorks Therapeutics' management team includes the following people:
  • Mr. Saqib Islam, CEO & Director (Age 49)
  • Dr. Jens Renstrup M.B.A., M.D., Chief Medical Officer (Age 54)
  • Dr. Badreddin Edris Ph.D., Chief Bus. Officer (Age 32)
  • Dr. Stephen P. Squinto, Acting Head of R&D and Director (Age 63)
  • Mr. Francis I. Perier Jr., Chief Financial Officer (Age 59)

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $46.58.

How big of a company is SpringWorks Therapeutics?

SpringWorks Therapeutics has a market capitalization of $2.00 billion. The company earns $-58,310,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis. SpringWorks Therapeutics employs 52 workers across the globe.

What is SpringWorks Therapeutics' official website?

The official website for SpringWorks Therapeutics is www.springworkstx.com.

How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company can be reached via phone at 203-883-9490 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.